Shengwei Mo

564 total citations
30 papers, 348 citations indexed

About

Shengwei Mo is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Shengwei Mo has authored 30 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 8 papers in Immunology and 6 papers in Surgery. Recurrent topics in Shengwei Mo's work include Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Neuroendocrine Tumor Research Advances (6 papers). Shengwei Mo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Neuroendocrine Tumor Research Advances (6 papers). Shengwei Mo collaborates with scholars based in China and United States. Shengwei Mo's co-authors include Shuangni Yu, Jie Chen, Zhaohui Lu, Liju Zong, Yang Xiang, Ming Zhang, Heng Ma, Xinxin Mao, Jie Chen and Wei‐Min Tong and has published in prestigious journals such as Gut, Scientific Reports and Cell Death and Differentiation.

In The Last Decade

Shengwei Mo

26 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shengwei Mo China 11 217 157 93 56 50 30 348
Jodi A. McKenzie United States 8 121 0.6× 81 0.5× 155 1.7× 54 1.0× 73 1.5× 30 302
Sho Tachino Japan 5 258 1.2× 112 0.7× 58 0.6× 49 0.9× 104 2.1× 6 410
Zhongmin Maxwell Wang Australia 10 210 1.0× 117 0.7× 49 0.5× 17 0.3× 70 1.4× 17 330
Perrine Garde‐Granger Canada 11 166 0.8× 117 0.7× 125 1.3× 52 0.9× 36 0.7× 12 349
Kotaro Shimura Japan 10 212 1.0× 179 1.1× 81 0.9× 64 1.1× 31 0.6× 20 365
Moran Yang China 10 189 0.9× 232 1.5× 107 1.2× 67 1.2× 57 1.1× 15 369
Félix Blanc‐Durand France 11 171 0.8× 64 0.4× 103 1.1× 41 0.7× 89 1.8× 40 303
Brian C. Willis United States 7 162 0.7× 54 0.3× 79 0.8× 52 0.9× 48 1.0× 9 305
Mengdi He China 9 181 0.8× 222 1.4× 92 1.0× 56 1.0× 53 1.1× 12 338
Yasmine Baca United States 10 174 0.8× 34 0.2× 94 1.0× 75 1.3× 83 1.7× 56 292

Countries citing papers authored by Shengwei Mo

Since Specialization
Citations

This map shows the geographic impact of Shengwei Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengwei Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengwei Mo more than expected).

Fields of papers citing papers by Shengwei Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengwei Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengwei Mo. The network helps show where Shengwei Mo may publish in the future.

Co-authorship network of co-authors of Shengwei Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Shengwei Mo. A scholar is included among the top collaborators of Shengwei Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengwei Mo. Shengwei Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Yilin, Pengyan Wang, Xiaoyan Chang, et al.. (2025). Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis. Diagnostic Pathology. 20(1). 55–55. 1 indexed citations
3.
Hu, Ya, Shengwei Mo, Ming Cui, et al.. (2024). The significance of an immunohistochemical marker-based panel in assisting the diagnosis of parathyroid carcinoma. Endocrine. 84(3). 1146–1153. 6 indexed citations
4.
Mo, Shengwei, Xinxin Mao, Wei‐Min Tong, et al.. (2023). Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma. Cell Death and Differentiation. 30(8). 1988–2004. 29 indexed citations
5.
Zong, Liju, Shengwei Mo, Zhaohui Lu, et al.. (2023). Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas. Journal of Clinical Medicine. 12(2). 530–530. 9 indexed citations
6.
Liu, Yilin, Zhaohui Lu, Xiaoyan Chang, et al.. (2023). Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence. Gynecologic Oncology. 176. 106–114. 1 indexed citations
7.
8.
Mo, Shengwei, et al.. (2023). Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas. Modern Pathology. 36(9). 100223–100223. 5 indexed citations
9.
Mo, Shengwei, Xinxin Mao, Yilin Liu, et al.. (2023). The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Theranostics. 13(13). 4601–4614. 9 indexed citations
10.
Mo, Shengwei, et al.. (2023). The tumoral microbiome of pancreatic intraductal papillary mucinous neoplasm: A single‐center retrospective cohort study. Journal of Gastroenterology and Hepatology. 39(3). 496–505. 3 indexed citations
11.
Zong, Liju, et al.. (2023). B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile. Archives of Pathology & Laboratory Medicine. 147(11). 1288–1297. 7 indexed citations
12.
Mo, Shengwei, et al.. (2022). Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma. The Journal of Pathology Clinical Research. 8(3). 268–278. 25 indexed citations
13.
Mo, Shengwei, et al.. (2022). PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. The Journal of Pathology Clinical Research. 8(3). 257–267. 12 indexed citations
14.
15.
16.
Mo, Shengwei, Liju Zong, Mei Li, et al.. (2022). Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors. Archives of Pathology & Laboratory Medicine. 147(2). 193–201. 5 indexed citations
17.
Mo, Shengwei, Zhaohui Lu, Congwei Jia, et al.. (2021). Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort. Neuroendocrinology. 112(5). 510–522. 3 indexed citations
18.
Zong, Liju, Shengwei Mo, Zhaohui Lu, et al.. (2021). Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer. Modern Pathology. 35(2). 266–273. 27 indexed citations
19.
Mo, Shengwei, Liju Zong, Xiaoyan Chang, et al.. (2021). High Mast Cell Density Predicts a Favorable Prognosis in Patients with Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology. 112(9). 845–855. 10 indexed citations
20.
Zhang, Yue, Jie Yan, Xiaoyan Chang, et al.. (2021). Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC. OncoTargets and Therapy. Volume 14. 2163–2175. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jodi A. McKenzie Breakdown of academic impact, for papers by Sho Tachino Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Perrine Garde‐Granger Breakdown of academic impact, for papers by Kotaro Shimura Breakdown of academic impact, for papers by Moran Yang Breakdown of academic impact, for papers by Félix Blanc‐Durand Breakdown of academic impact, for papers by Brian C. Willis Breakdown of academic impact, for papers by Mengdi He Breakdown of academic impact, for papers by Yasmine Baca
Rankless by CCL
2026